Vision Loss After Plaque Radiotherapy for Posterior Uveal Melanoma

Immunotherapy has dramatically improved outcomes for many patients with advanced melanoma. These treatments work by helping the immune system recognize and attack cancer cells. However, not all patients benefit from immunotherapy, and some develop resistance. Understanding why this happens is critical to improving treatment outcomes.
Recent research has shown that gut bacteria can influence how well immunotherapy works in melanoma. Much less is known about the bacteria in the mouth and overall oral health, even though oral health problems are common and can affect inflammation and immune function throughout the body. Inflammation of the gums and disruptions in oral microbes have been linked to chronic inflammation and alterations of the immune system, which may impact how patients respond to immunotherapy.

This study will explore whether oral health, bacteria found in saliva, and bacteria found in stool are associated with how patients with melanoma respond to immunotherapy. Patients starting immunotherapy will be asked to provide saliva and stool samples before treatment begins and again during treatment. Participants will also complete short, validated surveys about their oral health and dietary habits. These samples will be analyzed using established laboratory methods to identify and compare bacterial patterns in the mouth and gut.

Information about treatment response and side effects will be obtained from the medical record. By comparing oral health measures and bacterial patterns with treatment outcomes, this study aims to identify early signals that may help explain why some patients respond better to immunotherapy than others.

The results will guide future research aimed at understanding how oral health and the microbiome influence cancer treatment and may ultimately lead to new strategies to improve immunotherapy effectiveness for patients with melanoma.